Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Oct 22, 2024
Product Development
Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy
BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Jan 10, 2023
Regulation
Jan. 9 Quick Takes: Arrowhead falls on unexpected high placebo response in AAT study
Plus updates from BioMarin, Santhera-ReveraGen, Day One and more
BioCentury | Dec 20, 2022
Deals
Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal
Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more
BioCentury | Feb 11, 2022
Distillery Therapeutics
Structure-based design of antipsychotic without motor side effects
BioCentury | Aug 26, 2021
Finance
Neurogastrx: $60M crossover round to advance de-risked GI assets
Emerging Company Profile: Funding, assist from Vivo to land Phase III-ready Daewoong asset readies biotech to build on its CEO’s Ironwood roots
BioCentury | Feb 28, 2020
Product Development
Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI
BioCentury | Oct 21, 2019
Emerging Company Profile
Inscopix: scoping out better preclinical models via live brain imaging
Inscopix uses brain imaging to make better preclinical models for CNS diseases
BioCentury | May 31, 2019
Translation in Brief
New target for Oncoceutics' GPCR-targeting compounds
Oncoceutics' compounds increase mitochondrial protease activity to kill cancer
Items per page:
1 - 10 of 484